Delving into the Latest Updates on Ofloxacin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid, floxacin and Sodium Chloride, Of1oxacin

+ [54]

Target

Bacterial DNA gyrase x Bacterial top IV

Mechanism

Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

Corneal UlcerTrachomaBlepharitis+ [7]

Inactive Indication

Acute otitis media

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.Allergan, Inc.

Livzon Group Livzon Pharmaceutical Factory

+ [2]

Inactive Organization

Janssen Pharmaceuticals, Inc.Daiichi Pharmaceutical Co., Ltd.

Daiichi Sankyo, Inc.

Drug Highest PhaseApproved

First Approval Date

JP (16 Apr 1985),

Bacterial InfectionsOtitis ExternaOtitis Media

RegulationOrphan Drug (US), Orphan Drug (JP)

Login to view First Approval Timeline

Structure

Molecular FormulaC18H20FN3O4

InChIKeyGSDSWSVVBLHKDQ-UHFFFAOYSA-N

CAS Registry82419-36-1

Chronic endometritis (CE) is characterized by the presence of atypical plasma cell infiltrates (CD138 positive) in the endometrial stroma. Recent analyzes suggest that CE adversely affects fertility by reducing endometrial receptivity, impairing decidualization and uterine contractility, thus increasing the risk of recurrent pregnancy loss and implantation failure. It is likely that a significant proportion of idiopathic infertility cases are due to CE. The diagnosis of CE is a challenge because the clinical examination and transvaginal ultrasonography are considered non-specific. The recent scientific research has been aimed at identifying hysteroscopic CE diagnostic criteria and establishing the compatibility of ultrasonographic, hysteroscopic, histopathological (including the use of immunohistochemical testing with antibodies against human CD138) and microbiological diagnoses. Preliminary literature results suggested that successful treatment of CE with antibiotics could improve live birth rates.

Start Date01 Apr 2021

Sponsor / Collaborator

Uniwersytet Jagiellonski

100 Clinical Results associated with Ofloxacin

Login to view more data

100 Translational Medicine associated with Ofloxacin

Login to view more data

100 Patents (Medical) associated with Ofloxacin

Login to view more data

7,205

Literatures (Medical) associated with Ofloxacin

01 Jun 2024·Food chemistry

A dual-mode fluorescence and colorimetric sensing platform for efficient detection of ofloxacin in aquatic products using iron alkoxide nanozyme

Article

Author: Ding, Xiaodan ; Rong, Yawen ; Chen, Quansheng ; Ouyang, Qin ; Ahmad, Waqas ; Wu, Jizhong

Trace detection of ofloxacin (OFL) with high sensitivity, reliability, and visual clarity is challenging. To address this, a novel dual-modal aptasensor with fluorescence-colorimetric capabilities was designed that exploit the target-induced release of 3,3',5,5'-tetramethylbenzidine (TMB) molecules from aptamer-gated mesoporous silica nanoparticles (MSNs), the oxidase-like activity of iron alkoxide (IA) nanozyme, and the fluorescence attributes of core-shell upconversion nanoparticles. Therefore, the study reports a dual mode detection, with a fluorescence detection range for OFL spanning from 0.1 μg/kg to 1000 μg/kg (and a detection limit of 0.048 μg/kg). Additionally, the colorimetric method offered a linear detection range of 0.3 μg/kg to 1000 μg/kg, with a detection limit of 0.165 μg/kg. The proposed biosensor had been successfully applied to the determination of OFL content in real samples with satisfactory recoveries (78.24-96.14 %).

01 May 2024·Talanta

A novel synchronous fluorescence spectrometry combined with fluorescence sensitization for the highly sensitive and simultaneous detection of enoxacin, ofloxacin and tetracycline hydrochloride residues in wastewater

Article

Author: Xie, Lingfang ; Wang, Menglin ; Zheng, Xiaodan ; Zhang, Shiqi ; Yangcuo, Zhima ; Cai, Qihong

The synergistic effect of sodium dodecyl sulfate (SDS) and Mg²⁺ could significantly enhance the fluorescence intensity of enoxacin (ENO) at λ_ex/λ_em = 269.2 nm/385.6 nm, ofloxacin (OFL) at λ_ex/λ_em = 290.8 nm/466.2 nm and tetracycline hydrochloride (TCH) at λ_ex/λ_em = 372.6 nm/514.8 nm. Moreover, when the wavelength difference (Δλ) was chosen 135 nm, the synchronous fluorescence spectra of the three antibiotic complexes could be well separated and the interference of the samples matrix were eliminated primely. Therefore, only one synchronous fluorescence scan was needed to simultaneously determine the three antibiotics. Based on these facts, a synchronous fluorescence spectrometry combining fluorescence sensitization for highly sensitive and selective determination of ENO, OFL and TCH residues in wastewater was developed for the first time. The experimental results showed that the concentrations of ENO, OFL and TCH in the range of 0.5-550 ng mL^-1, 1-1500 ng mL^-1 and 10-5500 ng mL^-1 showed a good linear relationship with fluorescence intensity. The limits of detection were 0.0599 ng mL^-1, 0.115 ng mL^-1 and 0.151 ng mL^-1, respectively. The recoveries of the actual sample were 87.50%-99.99 %, 93.00%-98.50 % and 85.70%-98.42 %, respectively. Overall, the novel synchronous fluorescence spectrometry established in the experiment has the advantages of high sensitivity, good selectivity, fast detection speed and high accuracy. It has been successfully applied to the detection of residual amounts of ENO, OFL and TCH in wastewater with satisfactory results.

01 Apr 2024·Environmental research

Ofloxacin weakened treatment performance of rural domestic sewage in an aerobic biofilm system by affecting biofilm resistance, bacterial community, and functional genes

Article

Author: Chen, Juan ; Gao, Han ; Wang, Chao ; You, Guoxiang ; Han, Shanrui ; Lin, Junkai ; Ma, Junchao ; Feng, Bingbing

Ofloxacin (OFL) is a typical fluoroquinolone antibiotic widely detected in rural domestic sewage, however, its effects on the performance of aerobic biofilm systems during sewage treatment process remain poorly understood. We carried out an aerobic biofilm experiment to explore how the OFL with different concentrations affects the pollutant removal efficiency of rural domestic sewage. Results demonstrated that the OFL negatively affected pollutant removal in aerobic biofilm systems. High OFL levels resulted in a decrease in removal efficiency: 9.33% for chemical oxygen demand (COD), 18.57% for ammonium (NH₄⁺-N), and 8.49% for total phosphorus (TP) after 35 days. The findings related to the chemical and biological properties of the biofilm revealed that the OFL exposure triggered oxidative stress and SOS responses, decreased the live cell number and extracellular polymeric substance content of biofilm, and altered bacterial community composition. More specifically, the relative abundance of key genera linked to COD (e.g., Rhodobacter), NH₄⁺-N (e.g., Nitrosomonas), and TP (e.g., Dechlorimonas) removal was decreased. Such the OFL-induced decrease of these genera might result in the down-regulation of carbon degradation (amyA), ammonia oxidation (hao), and phosphorus adsorption (ppx) functional genes. The conventional pollutants (COD, NH₄⁺-N, and TP) removal was directly affected by biofilm resistance, functional genes, and bacterial community under OFL exposure, and the bacterial community played a more dominant role based on partial least-squares path model analysis. These findings will provide valuable insights into understanding how antibiotics impact the performance of aerobic biofilm systems during rural domestic sewage treatment.

1

News (Medical) associated with Ofloxacin

30 Jan 2023

·www.prnewswire.com

Study Concludes Enzyme-Based Advanced Formula ZYMOX® Otic Plus Beneficial

New Research Published Examines ZYMOX® Otic Plus on Canine Otitis Externa and Removal of Biofilms WESTMONT, Ill., Jan. 30, 2023 /PRNewswire/ -- PKB Animal Health, the industry leader in enzyme-based dermatology and oral care products for animals, announced the Polish Journal of Veterinary Sciences has published findings from a recent study on the effects of ZYMOX Otic Plus on canine otitis externa and removal of biofilms. The study evaluated in detail the in vivo and in vitro efficacy and concluded ZYMOX Otic Plus to be effective and beneficial for the management of canine otitis externa. Canine otitis externa is a common problem affecting a large percentage of dogs and cats, yet antibiotic resistance represents a major challenge to its treatment. While it is believed that bacteria and yeast produce biofilm structures that result in persistent conditions that are not responsive to traditional antibiotic therapeutics, ZYMOX Otic Plus contains a combination of enzymes including the biofilm-degrading enzymes mutanase and dextranase. The results of this study demonstrate the viability of ZYMOX Otic Plus as an alternative to antibiotics. Additional studies on ZYMOX efficacy have been published in the International Journal of Applied Veterinary Research on antibiofilm efficacy and a broad range of microorganisms, including Pseudomonas aeruginosa, Malassezia, and Methicillin-resistant Staphylococcus aureus (MRSA). Visit zymox.com to learn more about the Advanced Formula ZYMOX Otic Plus and the full line Dermatology products. About PKB Animal Health Pet King Brands, dba PKB Animal Health, the maker of ZYMOX® Ear and Skin products, Oratene® Brushless Oral Care, Equine Defense®, and ZYLAFEN® is a leader in veterinarian-approved pet products made in the USA. Focused on the health and wellness of small and large animals of all ages, the products utilize the Power of the LP3 Enzyme System and have been Resolving Ear, Skin, and Oral Conditions for Over 25 Years. Led by President and Founder, Pamela Bosco, who first introduced ZYMOX in 1998 with the help of her bio scientist brother, Michael Pellico, Pet King Brands has revolutionized the way people care for animals' ears, skin, and mouth offering solutions that are gentle to the animal, easy to administer and free of harsh chemicals and antibiotics. Media Contact: [email protected] SOURCE PKB Animal Health

Drug Approval

100 Deals associated with Ofloxacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00453	Ofloxacin	S01AE01 S02AA16 J01MA01	DB01165

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	US	Daiichi Pharmaceutical Co., Ltd.	16 Dec 1997
Conjunctivitis	US	Janssen Pharmaceuticals, Inc.	28 Dec 1990
Corneal Ulcer	US	Janssen Pharmaceuticals, Inc.	28 Dec 1990
Trachoma	JP	Santen Pharmaceutical Co., Ltd.	01 Jun 1989
Blepharitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Dacryocystitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Hordeolum	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Keratitis	JP	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Bacterial Infections	JP	Novartis Pharma AG	16 Apr 1985
Otitis Externa	JP	Alfresa Pharma Corp.	16 Apr 1985
Otitis Media	JP	Alfresa Pharma Corp.	16 Apr 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	Phase 3	-	Daiichi Sankyo, Inc.	01 Nov 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02528123 (CTgov)	Not Applicable	Myopia	114	Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin	uwabxhubfo(qwjqrqnygn) = nrlhcmaefg itbkukniqi (hepfzgolus, ohbknawjrw - vextxbhnjt) View more	-	23 Apr 2024
NCT02567825 (CTgov)	Not Applicable	Acute otitis media	250	Tympanostomy tube placement+Ofloxacin Otic (Surgical Management)	gijmkmngsi(hdbbxnzvpt) = wdxxtnmvbe jwusiadaip (jrlqmonild, wghgtgkzmt - wukilfrvob) View more	-	10 Dec 2021
				Ceftriaxone+Amoxicillin-Clavulanate (Non-Surgical Management)	gijmkmngsi(hdbbxnzvpt) = wzjdliqswp jwusiadaip (jrlqmonild, ocqgqibnkk - qnkriyoyrw) View more
NCT02373137 (CTgov)	Phase 4	Corneal Diseases \| Keratoplasty rejection	38	DMEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DMEK)	cidcdphnmz(llatxkuroe) = rytcjrqkdm ohbpsuyfdo (mevmzqegvj, lwiztnwkbx - yircqhhtts) View more	-	02 Jul 2019
				DSAEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DSAEK)	upotwzsqwx(lqnxgghhey) = gwdocnyazu zxgsbbtvwi (fyearpjdxd, hxsmjlupjt - sijlpnzwjd) View more
IAS2009	Not Applicable	Tuberculosis \| Acquired Immunodeficiency Syndrome	8	ofloxacin (Patients with multi-drug resistant tuberculosis)	evipofysrc(uzmozmsosp) = qavwwzfutu xloilyzbia (nrxgjglvyw ) View more	-	01 Jan 2009
				ofloxacin (Patients co-infected with multi-drug resistant tuberculosis and HIV/AIDS)	evipofysrc(uzmozmsosp) = eauuawqevw xloilyzbia (nrxgjglvyw ) View more
ISRCTN11871179 (Pubmed \| BMC Infect Dis)	Not Applicable	Brucellosis	-	Ofloxacin plus rifampicin	xdccnoljof(urwnyzojap) = pqtdxezuxg zbqntyavbr (zwmvqeerxd, 48 - 216)	-	23 Jun 2004
				Doxycycline plus rifampicin	xdccnoljof(urwnyzojap) = dknjecfwic zbqntyavbr (zwmvqeerxd, 48 - 262)